Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration

Current Opinion in Ophthalmology

Volumn 22, Issue 3, 2011, Pages 152-158

  Abouammoh, Marwan ^a,c   Sharma, Sanjay ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b HOTEL DIEU HOSPITAL   (Canada)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

adverse events; bevacizumab; effectiveness; incremental cost effectiveness ratio; intraocular inflammation; ranibizumab; safety

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE;

ARTERIAL THROMBOEMBOLISM; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENDOPHTHALMITIS; EYE DISEASE; HUMAN; INCIDENCE; INTRAOCULAR INFLAMMATION; IRIDOCYCLITIS; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; SYSTEMATIC REVIEW; THROMBOEMBOLISM; UVEITIS; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79955051062     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32834595d0     Document Type: Article

References (41)

1. Bressler NM, Bressler SB, Congdon NG, et al. Potential public health impact of age-related eye disease study results: AREDS Report No. 11. Arch Ophthalmol 2003; 121:1621-1624. (Pubitemid 37392370)
2. Brown MM, Brown GC, Sharma S, et al. Age-Related Eye Disease Study Research Group. The burden of age-related macular degeneration: a valuebased analysis. Curr Opin Ophthalmol 2006; 17:257-266. (Pubitemid 44309749)
3. Buch H, Vinding T, Nielsen NV. Prevalence and causes of visual impairment according to World HealthOrganization and United States criteria in an aged, urban Scandinavian population: the Copenhagen City Eye Study. Ophthalmology 2001; 108:2347-2357. (Pubitemid 33096957)
4. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004; 122:564-572. (Pubitemid 38456293)
5. Wells JA, Murthy R, Chibber R, et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol 1996; 80:363-366. (Pubitemid 26113591)
6. Los M, Roodhart JM, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. The Oncologist 2007; 12:443-450. (Pubitemid 46698722)
7. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36:331-335. (Pubitemid 41073112)
8. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med 2006; 355:1419-1431. (Pubitemid 44511557)
9. Chang TS, Bressler NM, Fine JT, et al. Improved vision-related function after ranibizumab treatment of neovascular age-relatedmacular degeneration: results of a randomized clinical trial. Arch Ophthalmol 2007; 125:1460-1469. (Pubitemid 350106676)
10. Bressler NM, Chang TS, Suñer IJ, et al. Vision-related function after ranibizumab treatment by better- or worse-seeing eye. Clinical trial results from MARINA and ANC.H.OR. Ophthalmology 2010; 117:747-756.
11. Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007; 114:246-252. (Pubitemid 46172497)
12. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1432-1444. (Pubitemid 44511558)
13. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANC.H.OR study. Ophthalmology 2009; 116:57-65.
14. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANC.H.OR results. Am J Ophthalmol 2007; 144:850-857.
15. Bressler NM, Chang TS, Fine JT, et al. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Arch Ophthalmol 2009; 127:13-21.
16. Bashshur ZF, Schakal A, Hamam RN, et al. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol 2007; 125:1357-1361. (Pubitemid 47606600)
17. Weigert G, Michels S, Sacu S, et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 2008; 92:356-360 (Pubitemid 351363530)
18. Modarres M, Naseripour M, Falavarjani KG, et al. Intravitreal injection of 2.5mg versus 1.25 mg bevacizumab (Avastin) for treatment of CNV associated with AMD. Retina 2009; 29:319-324.
19. Potter MJ, Claudio CC, Szabo SM. A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study. Br J Ophthalmol 2010; 94:174-179.
20. Costagliola C, Romano MR, Rinaldi M, et al. Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Br J Ophthalmol 2010; 94:180-184; Epub 2009 Dec 3.
21. Tufail A, Patel P, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicenter randomised double masked study. BMJ 2010; 340:c2459; doi: 10.1136/bmj.c2459.
22. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006; 124:1532-1542. (Pubitemid 44748725)
23. Antoszyk AN, Tuomi L, Chung CY, Singh A. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008; 145:862-874.
24. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, shamcontrolled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145:239-248.
25. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006; 113:633 e1-633 e4.
26. Luu ST, Gray T, Warrier SK, et al. Retrospective study of an as required dosing regimen of intravitreal bevacizumab in neovascular age-related macular degeneration in an Australian population. Clin Experiment Ophthalmol 2010; 38:659-663.
27. Fong DS, Custis P, Howes J, et al. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration: a multicenter, retrospective study. Ophthalmology 2010; 117:298-302.
28. Chong DY, Anand R, Williams PD, et al. Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection. Retina 2010; 30:1432-1440.
29. Johnson D, Hollands H, Hollands S, et al. Incidence and characteristics of acute intraocular inflammation after intravitreal injection of bevacizumab: a retrospective cohort study. Can J Ophthalmol 2010; 45:239-242.
30. Curtis L, Hammil BG, Schulman KA, et al. Risks of mortality, myocardial infarction, bleeding, stroke, associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010; 128:1273-1279.
31. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99:1232-1239. (Pubitemid 47299901)
32. Sharma S, Johnson D, Abouammoh M, et al. A retrospective analysis of the comparative safety and efficacy of intravitreal bevacizumab versus ranibizumab. Vancouver: ASRS; 2010.
33. Subramanian ML, Ness S, Abedi G, et al. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double masked, randomised clinical trial. Am J Ophthalmol 2009; 148:875-882.
34. Subramanian ML, Abedi G, Ness S, et al. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, doublemasked randomized clinical trial. Eye (Lond) 2010 [Epub ahead of print].
35. CATT study. http://clinicaltrials.gov/ct2/show/NCT00593450. [Accessed 7 November 2010]
36. IVAN study. http://www.controlled-trials.com/ISRCTN92166560. [Accessed November 2010]
37. VIBERA study. http://clinicaltrials.gov/ct2/show/NCT00559715. [Accessed November 2010].
38. MANTA study. http://clinicaltrials.gov/ct2/show/NCT00710229. [Accessed November 2010]
39. LUCAS study. http://clinicaltrials.gov/ct2/show/NCT01127360. [Accessed November 2010].
40. GEFAL study. http://clinicaltrials.gov/ct2/show/NCT01170767. [Accessed November 2010]
41. EQUAL study. http://apps.who.int/trialsearch. NTR1331. [Accessed 7 November 2010].